The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01X | Other antineoplastic agents | |
4
|
L01XL | Antineoplastic cell and gene therapy | |
5
|
L01XL11 |
| Active Ingredient |
|---|
|
Lifileucel is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The specific mechanism of action of lifileucel is unknown. |
| Document | Type | Information Source | |
|---|---|---|---|
| AMTAGVI Suspension for intravenous infusion | MPI, US: SPL/PLR | FDA, National Drug Code (US) |